GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyfuse Biomedical KK (TSE:4892) » Definitions » Gross-Profit-to-Asset %

Cyfuse Biomedical KK (TSE:4892) Gross-Profit-to-Asset % : 2.45% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Cyfuse Biomedical KK Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cyfuse Biomedical KK's annualized Gross Profit for the quarter that ended in Dec. 2023 was 円102.67 Mil. Cyfuse Biomedical KK's average Total Assets over the quarter that ended in Dec. 2023 was 円4,193.47 Mil. Therefore, Cyfuse Biomedical KK's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 2.45%.


Cyfuse Biomedical KK Gross-Profit-to-Asset % Historical Data

The historical data trend for Cyfuse Biomedical KK's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyfuse Biomedical KK Gross-Profit-to-Asset % Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
3.05 23.57 6.47 0.84

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only 2.06 0.33 0.50 0.23 2.45

Competitive Comparison of Cyfuse Biomedical KK's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Gross-Profit-to-Asset % falls into.



Cyfuse Biomedical KK Gross-Profit-to-Asset % Calculation

Cyfuse Biomedical KK's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=37.743/( (4815.337+4214.809)/ 2 )
=37.743/4515.073
=0.84 %

Cyfuse Biomedical KK's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=102.668/( (4172.122+4214.809)/ 2 )
=102.668/4193.4655
=2.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Cyfuse Biomedical KK Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cyfuse Biomedical KK's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyfuse Biomedical KK (TSE:4892) Business Description

Traded in Other Exchanges
N/A
Address
3-5-27, Mita, West Wing-1st Floor. Sumitomo Fudosan Mita Twin Building, Minato-ku, Tokyo, JPN
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine related products.

Cyfuse Biomedical KK (TSE:4892) Headlines

No Headlines